Literature DB >> 438280

[Permeability of N,N-bis(2-chloroethyl)-diamido-phosphoric-acid into tumor cells (author's transl)].

U Lenssen, H J Hohorst.   

Abstract

The uptake of tritiated N,N-bis(2-chloroethyl)-diamido-phosphoric-acid into Ehrlich-Ascites-Tumor cells of mice was studied by means of the siliconoil-filtration technique. At 10 mM concentration no permeation of the metabolite into the tumor cells could be found within 5 min at 1 degrees C, while its congenors cyclophosphamide and 4-hydroperoxycyclophosphamide (1 mM) were shown to permeate into the cells very easily reaching saturation values. Thus lack of permeation into tumor cells of N,N-bis(2-chloroethyl)-diamidophosphoric-acid seems to be the reason for the poor cytotoxic activity of this metabolite of cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 438280     DOI: 10.1007/bf00406573

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  6 in total

1.  Identification of phosphorodiamidic acid mustard as a human metabolite of cyclop hosphamide.

Authors:  C Fenselau; M N Kan; S Billets; M Colvin
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

2.  Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.

Authors:  T A Connors; P J Cox; P B Farmer; A B Foster; M Jarman
Journal:  Biochem Pharmacol       Date:  1974-01-01       Impact factor: 5.858

3.  Urinary metabolites of the antitumor agent cyclophosphamide.

Authors:  R F Struck; M C Kirk; L B Mellett; S el Dareer; D L Hill
Journal:  Mol Pharmacol       Date:  1971-09       Impact factor: 4.436

4.  Adenine nucleotide translocation of mitochondria. 1. Specificity and control.

Authors:  E Pfaff; M Klingenberg
Journal:  Eur J Biochem       Date:  1968-10-17

5.  Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells.

Authors:  U Draeger; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

6.  The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.

Authors:  H J Hohorst; U Draeger; G Peter; G Voelcker
Journal:  Cancer Treat Rep       Date:  1976-04
  6 in total
  4 in total

1.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].

Authors:  T Wagner; D Heydrich; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980-01       Impact factor: 4.553

3.  CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.

Authors:  R Schmidt; F Baumann; H Knüpfer; M Brauckhoff; L-C Horn; M Schönfelder; U Köhler; R Preiss
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

4.  Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.

Authors:  R F Struck; D J Dykes; T H Corbett; W J Suling; M W Trader
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.